

## 08. WHO consolidated guidelines for treatment of tuberculosis

**THE 46<sup>TH</sup> UNION  
WORLD CONFERENCE  
ON LUNG HEALTH**

CAPE TOWN, SOUTH AFRICA  
2-6 DECEMBER 2015

Thursday, 03 December 2015, 09:00 - 16:00

Room MR 2.40

Type of session	Workshop
Track	Drug-resistant TB care and treatment, including trials
Track2 (optional)	Drug-sensitive TB care and treatment, including trials
Organised by	World Health Organization (WHO)
Duration	Full-day
Max attendees	150
Meeting type	Open meeting
Description	In early 2015, the WHO began the process to update guidelines on treatment of DS-TB (2009) and the guidelines for programmatic management of DR-TB (2011). It is anticipated that by the time of the 46th Union World Conference on Lung Health, there will be a draft of the first WHO consolidated guidelines for the treatment of both DS-TB and DR-TB. The consolidated guidelines will be published in March 2016. The workshop will be an opportunity for participants to discuss the preliminary recommendations in the draft guidelines and to provide feedback to WHO before finalising the recommendations.
Target audience	<ol style="list-style-type: none"> <li>1. Physicians, nurses, NTP managers, and public health professionals</li> <li>2. Policy-makers, donors, academia, NGOs and international technical partners</li> </ol>
Objectives	<ol style="list-style-type: none"> <li>1. To present the process and methods applied by WHO for evidence synthesis and development of recommendations</li> <li>2. To present the main draft recommendations that will be part of the consolidated WHO TB treatment guidelines</li> <li>3. To provide a forum for a variety of stakeholders to provide feedback to WHO on the draft guidelines</li> </ol>
Expected outcome	1) Participants are informed about processes and methods applied by WHO for evidence synthesis and development of the up-coming consolidated guidelines on TB treatment of WHO; 2) Participants learn about the draft of evidenced-based recommendations for treatment of drug-susceptible TB (DS-TB), drug-resistant TB (DR-TB), HIV-positive TB, latent TB infection (LTBI) and other cross-cutting issues that will be part of WHO consolidated guidelines on TB treatment to be released in early 2016; 3) WHO gets feedback from participants on the draft of the recommendations for TB treatment presented at the workshop.
Keywords	Guideline; treatment; tuberculosis
Coordinator(s)	Ernesto Jaramillo (Switzerland), Linh Nguyen (Switzerland)
Chair(s)	Karin Weyer (South Africa), Bernard Fourie (South Africa)
Presentations	<ol style="list-style-type: none"> <li>1. Scope, processes of updating the guidelines and overview of GRADE assessment of evidence Dennis Falzon (Switzerland), Ernesto Jaramillo (Switzerland)</li> <li>2. Treatment of drug-susceptible TB: duration, frequency and composition of regimens for new and previously treated TB Giuliano Gargioni (Italy)</li> <li>3. Treatment of paediatric TB Stephen M Graham (Australia)</li> <li>4. Treatment of mono-/poly-resistant TB, rifampicin-resistant and MDR-TB Richard Menzies (Canada)</li> <li>5. Treatment of XDR-TB Charles Daley (USA)</li> <li>6. Treatment of drug-susceptible TB and drug-resistant TB for HIV-infected patients and TB preventive treatment for people living with HIV Avinash Kanchar (Switzerland)</li> <li>7. Preventive treatment for LTBI of drug-susceptible TB, drug-resistant-TB, in children and special situations Alberto Matteelli (Italy)</li> <li>8. Treatment adherence, models of care, social support and nutrition supplement Linh Nguyen (Switzerland)</li> <li>9. WHO guidance on ethics of TB prevention, diagnosis, treatment and care Ernesto Jaramillo (Switzerland)</li> <li>10. Safety of anti-TB drugs Antonia Kwiecien (USA)</li> </ol>